Skip to main content
$0.60 $0.02 (3.9%)

04:00 PM EDT on 09/29/23

Sangamo Biosciences, Inc. (NASDAQ:SGMO)

CAPS Rating: 5 out of 5

The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes.

Current Price $0.60 Mkt Cap $106.2M
Open $0.60 P/E Ratio -0.51
Prev. Close $0.60 Div. (Yield) $0.00 (0.0%)
Daily Range $0.58 - $0.65 Volume 2,471,007
52-Wk Range $0.56 - $5.07 Avg. Daily Vol. 1,544,739


How do you think NASDAQ:SGMO will perform against the market?

Add Stock to CAPS Watchlist

All Players

278 Outperform
15 Underperform

All-Star Players

49 Outperform
3 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:SGMO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

grahamfordummies (< 20)
Submitted May 23, 2013

Major disruptive technology shows early potential to cure HIV/AIDS. Disruption of the CCR5 gene appears to knock out the virus in circulating cells, but also in the reservoirs. Hence, a sustained viral response would be a cure, as no virus would… More

zzlangerhans (99.95)
Submitted December 01, 2008

Sangamo. The very name brings bile to my throat and sets an artery to throbbing in my temple. Much like the name Alamo might to a Texan. I knew this company was crap. I knew zinc fingers were bull. But I wanted to play them like a fish, letting them… More

Recent Community Commentary

Read the most recent pitches from players about SGMO.


Member Avatar HCKCharts15 (< 20) Submitted: 1/18/2021 8:39:54 AM : Outperform Start Price: $15.74 NASDAQ:SGMO Score: -109.39

SGMO is gaining relative strength vs S&P500, based on #rrgchart


Member Avatar Ejohm (< 20) Submitted: 12/19/2020 10:36:08 PM : Outperform Start Price: $13.50 NASDAQ:SGMO Score: -112.66

They never did before, except for a couple of blips. What makes you think they will do it now?


Member Avatar mdriver78 (63.29) Submitted: 7/10/2019 1:35:06 PM : Outperform Start Price: $10.70 NASDAQ:SGMO Score: -143.62

Sangamo is a gene therapy and human gene editing pioneer.

Founded in 1995, it’s one of the oldest biotechs in the gene editing business.

This means the company has spent a long time working out the kinks and fine-tuning its own unique gene editing platform, known as zinc finger nuclease (ZFN).

Last year, the company made history by launching the world’s first in vivo gene editing clinical trial.

Unlike other kinds of gene therapy, in vivo gene editing means actually fixing bad genes inside the body by adding corrections to existing nuclear DNA.

But SGMO has also become a gene therapy company — where a small piece of DNA is inserted into a cell in addition to existing material so that the cell can carry out its instructions.

This week, Sangamo announced promising news regarding one of its gene therapy programs for hemophilia A.

Many gene therapy companies are working on this bleeding disorder as well as its closely related cousin, hemophilia B.

In both cases, a miscoded gene blocks the production of a blood clotting protein necessary for life.

In the case of hemophilia A, the deficient protein is known as Factor VIII (antihemophilic factor).

Most gene therapy companies are working on hemophilia because it represents a “low-hanging fruit,” one of the easier targets for this new biotechnology — and one that would be worth many billions in annual sales.

But that doesn’t mean it’s been easy…

Getting a working Factor VIII gene into cells is tricky, requiring a careful design of viral vectors to do the job.

Sangamo may be on the right path with its hemophilia A gene therapy, SB-525.

A few days ago, the company and its Big Pharma partner Pfizer Inc. (PFE) presented some early data at a scientific conference.

Patients receiving the highest tested dose of SB-525 showed rapid, positive change.

Enough of their cells received the gene therapy to raise production of Factor VIII to normal levels and didn’t suffer the typical symptoms of hemophilia A, which involves bleeding.

This success is more than just a validation for Sangamo’s hemophilia program.

The high gene delivery validates the company’s gene delivery platform, which spans multiple indications in several different classes of gene-related disease.

Sangamo is still in early stages, but is well on its way to one day becoming a gene therapy powerhouse — if that’s allowed to happen…

Big Pharma and Big Biotech have recently shown a strong desire for acquiring gene therapy companies in order to take advantage of what this emerging biotechnology has to offer.


Find the members with the highest scoring picks in SGMO.

Score Leader


pick1998 (55.44) Score: +510.94

The Score Leader is the player with the highest score across all their picks in SGMO.

Member Name Member
Call Time
Score Commentary
pick1998 55.44 2/3/2009 Underperform 1Y $4.81 -87.46% +423.48% +510.94 1 Comment
anticitradeshort 28.07 4/20/2009 Underperform NS $4.66 -87.05% +404.95% +492.00 0 Comment
robo2011 41.83 11/17/2008 Underperform NS $2.49 -75.77% +408.36% +484.13 0 Comment
pita99 < 20 12/22/2008 Underperform 1Y $3.75 -83.91% +391.11% +475.02 3 Comments
longtermgrowth09 54.43 12/17/2009 Underperform 5Y $5.44 -88.91% +286.09% +375.00 0 Comment
jroren 97.40 6/21/2010 Underperform 3M $4.31 -86.00% +277.90% +363.90 0 Comment
Macthoy 82.23 11/16/2006 Underperform NS $6.12 -90.14% +222.02% +312.16 1 Comment
KLF284 < 20 5/16/2008 Underperform 3W $13.17 -95.42% +211.54% +306.96 0 Comment
cthomas1017 98.74 11/23/2012 Underperform 5Y $5.36 -88.74% +202.43% +291.17 0 Comment
ZBullDog 22.37 9/19/2007 Underperform 1Y $13.20 -95.43% +193.94% +289.36 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SGMO.